News
Rapid Activation to Screening and Enrolled 300% of the Goal in a Phase 3 Obesity & T2DM Trial
As obesity and type 2 diabetes mellitus (T2DM) continue to pose major public health challenges, up to 90% of adults with T2DM are classified as overweight or obese. Consequently, the demand for clinical trials to evaluate innovative therapies within tight operational windows and highly specific patient populations is at an...
Dr. Melita Tate on Her Research Journey and the Fight to End Obesity
Every January, Dr. Melita Tate sits down with a blank planner and gives herself ninety seconds to answer “The Three Most Important Questions.” – What do I want to experience? – How do I want to grow? – What do I want to contribute? A few years ago, in one...
Achieved 100% of the Enrollment Goal in a Phase 4 Obesity & Plaque Psoriasis Trial
While obesity remains one of the most widely studied indications in modern medicine, a major frontier of clinical research lies in addressing its interconnected comorbidities. Conditions like moderate-to-severe plaque psoriasis share inflammatory pathways, meaning metabolic and dermatological disease states frequently compound one another. Successfully evaluating therapies at this intersection requires...
DelRicht Achieves 276.7% of the Enrollment Goal in a U.S. Phase 3 Obesity Trial
In the evolving cardiometabolic landscape, obesity continues to be a leading public health challenge. In 2025, the World Obesity Federation reported that the total number of adults living with obesity is projected to increase to 1.13 billion by 2030. While FDA-approved therapeutics have expanded significantly in recent years, the demand...
Achieving Enrollment and Retention Success in a COVID-19 Vaccine Trial
As the public health landscape surrounding COVID-19 continues to develop, Phase 4 studies play an essential role in understanding long-term vaccine performance. Evaluating how approved vaccines perform in real-world settings requires a strong operational foundation, especially when managing the nuances of interventional protocols. Exceeding Expectations in COVID-19 Vaccine Research Selected...
DelRicht Achieves 3 Major Start-Up Milestones in an Hidradenitis Suppurativa Chronic Pain Trial
Evaluating complex immunological indications through digital health tools requires site infrastructure that moves as fast as the science, especially with Hidradenitis Suppurativa (HS), a debilitating, painful condition that presents immense daily challenges for patients. Success demands rapid site initiation, seamless technology onboarding, and proactive patient retention strategies. DelRicht Research delivers...
FDA Approves mFLUSIVA® Influenza Vaccine for Adults 50 Years of Age and Older
The U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), an influenza vaccine developed by Moderna Inc., to prevent seasonal flu and lower risk of serious illness and complications for adults 50 years of age and older. This approval represents Moderna’s fifth approved product and the first mRNA-based influenza...
DelRicht Achieves First Subject Enrolled Studywide in a Phase 3 Pneumococcal Vaccine Trial
DelRicht Research was selected as a participating site network for a Phase 3 Pneumococcal Vaccine trial enrolling healthy adults, 50+ years old, with most recent pneumococcal vaccines completed more than a year prior to the start of the study. From challenges including eligibility recruitment, protocol eDiary compliance, and technical barriers...
Delivering Expertise and Enrollment Success in Androgenetic Alopecia Research
Androgenetic alopecia (AGA) research presents a unique set of challenges for clinical trials. From the nuances of standardizing photographic endpoints to managing the high expectations of a motivated but discerning patient population, trials in this therapeutic area demand both clinical sensitivity and operational precision. DelRicht Research has built a reputation...
Dr. Melita Tate First Patient Screened Studywide in an Acute Migraine Trial
Congratulations to Dr. Melita Tate and the clinical research team at Grassroots Healthcare for recently setting a new benchmark by screening the first patient studywide. This Phase 3 migraine trial evaluates an oral therapeutic designed for acute treatment of migraine attacks in adults. This first patient screened milestone represents an...
